Trial Profile
A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (ING113097).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 02 Aug 2011 Actual patient number is 16 and additional trial investigator identified as reported by ClinicalTrials.gov.
- 02 Aug 2011 Actual patient number is 16 and additional trial investigator identified as reported by ClinicalTrials.gov.
- 26 Jul 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.